FindTrial
Sign In

Phase II, clinical trial, to evaluate OS in two cohorts in relapsed stage III non-small-cell lung cancer (NSCLC) pretreated with chemoradiotherapy and durvalumab

Status
Not yet recruiting
Phases
Phase 2
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2024-520081-65-00
Acronym
CONDOR
Enrollment
75
Registered
2025-02-20
Start date
Unknown
Completion date
Unknown
Last updated
2025-12-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

NSCLC non-small cell lung cancer

Brief summary

Overall survival (OS) in Cohort A and in Cohort B

Detailed description

The secondary endpoints are as follows: • progression-free survival (PFS) in Cohort A and in Cohort B; • objective response rate (ORR) in Cohort A and in Cohort B; • safety and incidence of AEs in each Cohort according to treatment; • PFS and overall survival (OS) according to biomarkers (i.e., PD-L1, ERCC1, SLFN11, STK11, KEAP1, p53 expression, DNA repair genes [including BRCA 1-2 mutations] and tumor mutational burden).

Interventions

DRUGIMFINZI 50 mg/mL concentrate for solution for infusion.

Sponsors

Fondazione Ricerca Traslazionale
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
Overall survival (OS) in Cohort A and in Cohort B—

Secondary

MeasureTime frame
The secondary endpoints are as follows: • progression-free survival (PFS) in Cohort A and in Cohort B; • objective response rate (ORR) in Cohort A and in Cohort B; • safety and incidence of AEs in each Cohort according to treatment; • PFS and overall survival (OS) according to biomarkers (i.e., PD-L1, ERCC1, SLFN11, STK11, KEAP1, p53 expression, DNA repair genes [including BRCA 1-2 mutations] and tumor mutational burden).—

Countries

Italy

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026